Tenderwize
Back to tender search

Open-house non-exclusive rebate agreement for Fusidinsäure/Betamethason

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Jul 31, 2027 · 295 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Fusidinsäure/Betamethason (ATC-Code nach WHO: D07CC01)

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

46 / 100

Complexity

58 / 100

Risk factors

Demand is explicitly unknown and depends on prescriptions, insured population development, and pharmacy stocking behavi...

The notice says the publication form contains technical placeholder fields with no substantive meaning for this Open-Ho...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Jul 31, 2027

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Non-exclusive rebate agreement for pharmaceutical products containing Fusidinsäure/Betamethason.
  • Open-House participation model with equal access for all interested qualifying pharmaceutical companies.
Show full summary

This is an Open-House pharmaceutical supply arrangement for Fusidinsäure/Betamethason (ATC D07CC01) led by AOK PLUS. It is non-exclusive, open to all qualifying pharmaceutical companies, with no individual negotiations and no guaranteed minimum purchase volume. Participation documents are available via DTVP, but the extracted procurement documents were not provided beyond the XML notice text, so document-specific instructions cannot be fully verified.

Risks

Demand is explicitly unknown and depends on prescriptions, insured population development, and pharmacy stocking behavi...

The notice says the publication form contains technical placeholder fields with no substantive meaning for this Open-Ho...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • The company must accept the participation conditions and the rebate agreement terms.

Eligibility

  • Submission of the completed declaration of non-existence of exclusion grounds is required.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Open-house non-exclusive rebate agreement for Fusidinsäure/Betamethason

Supply lot for non-exclusive pharmaceutical rebate agreements under § 130a(8) SGB V for the active substance Fusidinsäure/Betamethason (ATC D07CC01). The lot is an Open-House model, so any interested qualifying pharmaceutical company may join during the participation period. No exclusivity, no individual negotiations, and no guaranteed minimum purchase volume are stated. Performance/place of performance is Germany, specifically Dresden in the structured data.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Jul 2025 - Jul 2027

Category

Pharmaceutical products

Deadline

Deadline Jul 31, 2027

Procurement Details

Publication date
21 May 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
330350-2025

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30